Homepage
21900
employees
150
countries in
which the Group’s
medecines are distributed
> 20 %
of brand-name revenue
invested in R&D every year
4 therapeutic areas
oncology,
cardiometabolism, neuroscience
and immuno-inflammation
€5.3 billion euros
euros in revenue in 2022/2023
comprising €4 billion for brand-name medicines
and €1.3 billion for generic medicines.